Upadacitinib offers hope for refractory Crohn’s disease patients in phase 2 trial

– Sanborn discusses study results, JAK Inhibitors, IBD trial design Positive results of a phase 2 clinical trial of upadacitinib, an oral JAK1 inhibitor, in Crohn’s disease patients were presented during the Late-Breaking Abstract Plenary Session at Digestive Disease Week 2017 in Chicago. The CELEST dose ranging study demonstrated endoscopic improvement and clinical benefit of upadacitinib …

Continue reading Upadacitinib offers hope for refractory Crohn’s disease patients in phase 2 trial

Biosimilars in IBD – what patients need to know

In 2016 the US Food and Drug administration approved two biosimilar products which will be used in the treatment of inflammatory bowel disease in the near future. The FDA has approved Inflectra, a biosimilar to Janssen’s Remicade (infliximab) and Amjevita, a biosimilar to Abbvie’s Humira (adalimumab). What is a biosimilar? The FDA defines a biosimilar …

Continue reading Biosimilars in IBD – what patients need to know